Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom.

Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience

Lewis, Katharine L.
Chin, Collin K.
Manos, Kate
Casey, John
Hamad, Nada
Crawford, Julie
Ho, Shir-Jing
Issa, Samar
Grigg, Andrew
Wood, Peter
Gandhi, Maher K.
Do, Bryan
Nastoupil, Loretta
Hawkes, Eliza A.
Cheah, Chan Y.

July 2020

Primary and secondary central nervous system lymphomas (PCNSL/SCNSL) are aggressive rare malignancie...

lbrutinib (lmbruvica™) for Treatment of Mantle Cell Lymphoma

Crowe, Brittany
Hoffman, Joy
Stewart, Hannah
Steinbrunner, Alison
Olah, Mark E.

October 2019

Mantle cell lymphoma (MCL) is a rare and moderately aggressive form of non-Hodgkin\u27s lymphoma (NH...

© 2013 Chavez et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. Core Evidence 2013:8 37–45

Core Evidence
Julio C Chavez
Eva Sahakian
Javier Pinilla-ibarz
H Lee
Moffitt Cancer

August 2016

Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocyti...

Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom.

Tucker, D. L.
Naylor, G.
Kruger, A.
Hamilton, Malcolm
Follows, G.
Rule, S. A.

May 2016

This article is currently freely available from the publisher's site (May 2016). Click on the 'Addit...

Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties

Dreger, Peter
Michallet, Mauricette
Bosman, Paul
Dietrich, Sascha
Sobh, Mohamad
Boumendil, Ariane
Schaap, M.
Montoto, Silvia
Schetelig, Johannes

January 2019

Contains fulltext : 201051.pdf (publisher's version ) (Closed access

Ibrutinib Treatment through Nasogastric Tube in a Comatose Patient with Central Nervous System Localization of Mantle Cell Lymphoma

Tamim Alsuliman
Maifa Belghoul
Bachra Choufi

January 2018

Nowadays, mantle cell lymphoma is considered to have one of the worst prognostic profiles among lymp...

Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma

Broccoli, Alessandro
Casadei, Beatrice
Morigi, Alice
Sottotetti, Federico
Gotti, Manuel
Spina, Michele
Volpetti, Stefano
Ferrero, Simone
Spina, Francesco
Pisani, Francesco
Merli, Michele
Visco, Carlo
Paolini, Rossella
Zilioli, Vittorio Ruggero
Baldini, Luca
Di Renzo, Nicola
TOSI, PATRIZIA
Cascavilla, Nicola
Molica, Stefano
Ilariucci, Fiorella
Rigolin, Gian Matteo
D'Alò, Francesco
Vanazzi, Anna
Santambrogio, Elisa
Marasca, Roberto
Mastrullo, Lucia
Castellino, Claudia
Desabbata, Giovanni
Scortechini, Ilaria
Trentin, Livio
Morello, Lucia
Argnani, Lisa
Zinzani, Pier Luigi

January 2018

Although sometimes presenting as an indolent lymphoma, mantle cell lymphoma (MCL) is an aggressive d...

Italian real life experience with ibrutinib: Results of a large observational study on 77 relapsed/refractory mantle cell lymphoma

Broccoli A.
Casadei B.
Morigi A.
Sottotetti F.
Gotti M.
Spina M.
Volpetti S.
Ferrero S.
Spina F.
Pisani F.
Merli M.
Visco C.
Paolini R.
Zilioli V. R.
Baldini L.
Di Renzo N.
Tosi P.
Cascavilla N.
Molica S.
Ilariucci F.
Rigolin G. M.
D'Alo F.
Vanazzi A.
Santambrogio E.
Marasca R.
Mastrullo L.
Castellino C.
Desabbata G.
Scortechini I.
Trentin L.
Morello L.
Argnani L.
Zinzani P. L.

January 2018

Although sometimes presenting as an indolent lymphoma, mantle cell lymphoma (MCL) is an aggressive d...

Mantle Cell Lymphoma: Effectiveness of Maintenance Ibrutinib – Case Report

Krasowska, Danuta
Szczepanek, Aleksandra
Kozioł, Magdalena
Szczepanek-Wąsik, Ewa

September 2020

Krasowska Danuta, Szczepanek Aleksandra, Kozioł Magdalena, Szczepanek-Wąsik Ewa. Mantle Cell Lympho...

Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma

Maruyama, Dai
Nagai, Hirokazu
Fukuhara, Noriko
Kitano, Toshiyuki
Ishikawa, Takayuki
Shibayama, Hirohiko
Choi, Ilseung
Hatake, Kiyohiko
Uchida, Toshiki
Nishikori, Momoko
Kinoshita, Tomohiro
Matsuno, Yoshihiro
Nishikawa, Tomoaki
Takahara, Satoko
Tobinai, Kensei

December 2016

In this multicenter, single-arm, phase II study, the efficacy and safety of ibrutinib were examined ...

Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma:An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Tappenden, Paul
Simpson, Emma
Hamilton, Jean
Pollard, Daniel
Clowes, Mark
Kaltenthaler, Eva
Meiklejohn, David
Morley, Nick

March 2019

As part of its Single Technology Appraisal process, the UK National Institute for Health and Care Ex...

Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice

Vladimir I. Vorobyev
Eduard G. Gemdzhian
Liudmila V. Fedorova
Natalia B. Mikhailova
Ridvan K. Ilyasov
Liliia P. Kaleikina
Olga S. Trubyakova
Kamil D. Kaplanov
Elena V. Melnichenko
Elena V. Martynova
Elena P. Yakovleva
Olga Yu. Li
Elena V. Tarasenko
Elena P. Chumakova
Natalia B. Bulieva
Ekaterina S. Nesterova
Oleg V. Margolin
Vera A. Zherebtsova
Lev S. Butaev
Vadim V. Ptushkin

July 2021

Background. Mantle cell lymphoma (MCL) is a rare and clinically aggressive lymphoma subtype. Current...

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

Wang, Michael L.
Blum, Kristie A.
Martin, Peter
Goy, Andre
Auer, Rebecca
Kahl, Brad S.
Jurczak, Wojciech
Advani, Ranjana H.
Romaguera, Jorge E.
Williams, Michael E.
Barrientos, Jacqueline C.
Chmielowska, Ewa
Radford, John
Stilgenbauer, Stephan
Dreyling, Martin
Jedrzejczak, Wieslaw Wiktor
Johnson, Peter
Spurgeon, Stephen E.
Zhang, Liang
Baher, Linda
Cheng, Mei
Lee, Dana
Beaupre, Darrin M.
Rule, Simon

August 2015

Ibrutinib, an oral inhibitor of Bruton tyrosine kinase, is approved for patients with mantle cell ly...

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse

Rusconi, Chiara
Cheah, Chan Y.
Eyre, Toby A.
Tucker, David
Klener, Pavel
Giné, Eva
Crucitti, Lara
Muzi, Cristina
Iadecola, Sara
Infante, Gabriele
Bernard, Sophie
Auer, Rebecca L.
Pagani, Chiara
Duglosz-Danecka, Monika
Mocikova, Heidi
van Meerten, Tom
Cencini, Emanuele
Marin-Niebla, Ana
Williams, Michael E.
Angelillo, Piera
Nicoli, Paolo
Arcari, Annalisa
Morello, Lucia
Mannina, Donato
Vitagliano, Orsola
Sartori, Roberto
Chiappella, Annalisa
Sciarra, Roberta
Stefani, Piero M.
Dreyling, Martin
Seymour, John F.
Visco, Carlo

October 2022

Central nervous system (CNS) relapse of mantle cell lymphoma (MCL) is a rare phenomenon with dismal ...

Expanding horizons in the treatment of mantle cell lymphoma: Ibrutinib a novel BTK-targeting inhibitor

Dhingra, Sameer
Sachdeva, Mamta

January 2017

Mantle cell lymphoma (MCL) is a non-Hodgkin lymphoma characterized by involvement of the lymph nodes...

Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience

Lewis, Katharine L.
Chin, Collin K.
Manos, Kate
Casey, John
Hamad, Nada
Crawford, Julie
Ho, Shir-Jing
Issa, Samar
Grigg, Andrew
Wood, Peter
Gandhi, Maher K.
Do, Bryan
Nastoupil, Loretta
Hawkes, Eliza A.
Cheah, Chan Y.

July 2020

Primary and secondary central nervous system lymphomas (PCNSL/SCNSL) are aggressive rare malignancie...

lbrutinib (lmbruvica™) for Treatment of Mantle Cell Lymphoma

Crowe, Brittany
Hoffman, Joy
Stewart, Hannah
Steinbrunner, Alison
Olah, Mark E.

October 2019

Mantle cell lymphoma (MCL) is a rare and moderately aggressive form of non-Hodgkin\u27s lymphoma (NH...

© 2013 Chavez et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. Core Evidence 2013:8 37–45

Core Evidence
Julio C Chavez
Eva Sahakian
Javier Pinilla-ibarz
H Lee
Moffitt Cancer

August 2016

Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocyti...

Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom.

Tucker, D. L.
Naylor, G.
Kruger, A.
Hamilton, Malcolm
Follows, G.
Rule, S. A.

May 2016

This article is currently freely available from the publisher's site (May 2016). Click on the 'Addit...

Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties

Dreger, Peter
Michallet, Mauricette
Bosman, Paul
Dietrich, Sascha
Sobh, Mohamad
Boumendil, Ariane
Schaap, M.
Montoto, Silvia
Schetelig, Johannes

January 2019

Contains fulltext : 201051.pdf (publisher's version ) (Closed access

Ibrutinib Treatment through Nasogastric Tube in a Comatose Patient with Central Nervous System Localization of Mantle Cell Lymphoma

Tamim Alsuliman
Maifa Belghoul
Bachra Choufi

January 2018

Nowadays, mantle cell lymphoma is considered to have one of the worst prognostic profiles among lymp...

Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma

Broccoli, Alessandro
Casadei, Beatrice
Morigi, Alice
Sottotetti, Federico
Gotti, Manuel
Spina, Michele
Volpetti, Stefano
Ferrero, Simone
Spina, Francesco
Pisani, Francesco
Merli, Michele
Visco, Carlo
Paolini, Rossella
Zilioli, Vittorio Ruggero
Baldini, Luca
Di Renzo, Nicola
TOSI, PATRIZIA
Cascavilla, Nicola
Molica, Stefano
Ilariucci, Fiorella
Rigolin, Gian Matteo
D'Alò, Francesco
Vanazzi, Anna
Santambrogio, Elisa
Marasca, Roberto
Mastrullo, Lucia
Castellino, Claudia
Desabbata, Giovanni
Scortechini, Ilaria
Trentin, Livio
Morello, Lucia
Argnani, Lisa
Zinzani, Pier Luigi

January 2018

Although sometimes presenting as an indolent lymphoma, mantle cell lymphoma (MCL) is an aggressive d...

Italian real life experience with ibrutinib: Results of a large observational study on 77 relapsed/refractory mantle cell lymphoma

Broccoli A.
Casadei B.
Morigi A.
Sottotetti F.
Gotti M.
Spina M.
Volpetti S.
Ferrero S.
Spina F.
Pisani F.
Merli M.
Visco C.
Paolini R.
Zilioli V. R.
Baldini L.
Di Renzo N.
Tosi P.
Cascavilla N.
Molica S.
Ilariucci F.
Rigolin G. M.
D'Alo F.
Vanazzi A.
Santambrogio E.
Marasca R.
Mastrullo L.
Castellino C.
Desabbata G.
Scortechini I.
Trentin L.
Morello L.
Argnani L.
Zinzani P. L.

January 2018

Although sometimes presenting as an indolent lymphoma, mantle cell lymphoma (MCL) is an aggressive d...

Mantle Cell Lymphoma: Effectiveness of Maintenance Ibrutinib – Case Report

Krasowska, Danuta
Szczepanek, Aleksandra
Kozioł, Magdalena
Szczepanek-Wąsik, Ewa

September 2020

Krasowska Danuta, Szczepanek Aleksandra, Kozioł Magdalena, Szczepanek-Wąsik Ewa. Mantle Cell Lympho...

Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma

Maruyama, Dai
Nagai, Hirokazu
Fukuhara, Noriko
Kitano, Toshiyuki
Ishikawa, Takayuki
Shibayama, Hirohiko
Choi, Ilseung
Hatake, Kiyohiko
Uchida, Toshiki
Nishikori, Momoko
Kinoshita, Tomohiro
Matsuno, Yoshihiro
Nishikawa, Tomoaki
Takahara, Satoko
Tobinai, Kensei

December 2016

In this multicenter, single-arm, phase II study, the efficacy and safety of ibrutinib were examined ...

Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma:An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Tappenden, Paul
Simpson, Emma
Hamilton, Jean
Pollard, Daniel
Clowes, Mark
Kaltenthaler, Eva
Meiklejohn, David
Morley, Nick

March 2019

As part of its Single Technology Appraisal process, the UK National Institute for Health and Care Ex...

Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice

Vladimir I. Vorobyev
Eduard G. Gemdzhian
Liudmila V. Fedorova
Natalia B. Mikhailova
Ridvan K. Ilyasov
Liliia P. Kaleikina
Olga S. Trubyakova
Kamil D. Kaplanov
Elena V. Melnichenko
Elena V. Martynova
Elena P. Yakovleva
Olga Yu. Li
Elena V. Tarasenko
Elena P. Chumakova
Natalia B. Bulieva
Ekaterina S. Nesterova
Oleg V. Margolin
Vera A. Zherebtsova
Lev S. Butaev
Vadim V. Ptushkin

July 2021

Background. Mantle cell lymphoma (MCL) is a rare and clinically aggressive lymphoma subtype. Current...

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

Wang, Michael L.
Blum, Kristie A.
Martin, Peter
Goy, Andre
Auer, Rebecca
Kahl, Brad S.
Jurczak, Wojciech
Advani, Ranjana H.
Romaguera, Jorge E.
Williams, Michael E.
Barrientos, Jacqueline C.
Chmielowska, Ewa
Radford, John
Stilgenbauer, Stephan
Dreyling, Martin
Jedrzejczak, Wieslaw Wiktor
Johnson, Peter
Spurgeon, Stephen E.
Zhang, Liang
Baher, Linda
Cheng, Mei
Lee, Dana
Beaupre, Darrin M.
Rule, Simon

August 2015

Ibrutinib, an oral inhibitor of Bruton tyrosine kinase, is approved for patients with mantle cell ly...

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse

Rusconi, Chiara
Cheah, Chan Y.
Eyre, Toby A.
Tucker, David
Klener, Pavel
Giné, Eva
Crucitti, Lara
Muzi, Cristina
Iadecola, Sara
Infante, Gabriele
Bernard, Sophie
Auer, Rebecca L.
Pagani, Chiara
Duglosz-Danecka, Monika
Mocikova, Heidi
van Meerten, Tom
Cencini, Emanuele
Marin-Niebla, Ana
Williams, Michael E.
Angelillo, Piera
Nicoli, Paolo
Arcari, Annalisa
Morello, Lucia
Mannina, Donato
Vitagliano, Orsola
Sartori, Roberto
Chiappella, Annalisa
Sciarra, Roberta
Stefani, Piero M.
Dreyling, Martin
Seymour, John F.
Visco, Carlo

October 2022

Central nervous system (CNS) relapse of mantle cell lymphoma (MCL) is a rare phenomenon with dismal ...

Expanding horizons in the treatment of mantle cell lymphoma: Ibrutinib a novel BTK-targeting inhibitor

Dhingra, Sameer
Sachdeva, Mamta

January 2017

Mantle cell lymphoma (MCL) is a non-Hodgkin lymphoma characterized by involvement of the lymph nodes...

Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience

Lewis, Katharine L.
Chin, Collin K.
Manos, Kate
Casey, John
Hamad, Nada
Crawford, Julie
Ho, Shir-Jing
Issa, Samar
Grigg, Andrew
Wood, Peter
Gandhi, Maher K.
Do, Bryan
Nastoupil, Loretta
Hawkes, Eliza A.
Cheah, Chan Y.

July 2020

Primary and secondary central nervous system lymphomas (PCNSL/SCNSL) are aggressive rare malignancie...

lbrutinib (lmbruvica™) for Treatment of Mantle Cell Lymphoma

Crowe, Brittany
Hoffman, Joy
Stewart, Hannah
Steinbrunner, Alison
Olah, Mark E.

October 2019

Mantle cell lymphoma (MCL) is a rare and moderately aggressive form of non-Hodgkin\u27s lymphoma (NH...

© 2013 Chavez et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. Core Evidence 2013:8 37–45

Core Evidence
Julio C Chavez
Eva Sahakian
Javier Pinilla-ibarz
H Lee
Moffitt Cancer

August 2016

Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocyti...

Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom.

Abstract

Extracted data

Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom.

Abstract

Extracted data

Related items

Related items